Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -3 of 3
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Enrolling by invitation
18 and over
Pharmaceutical / Industry
114-NH-302
NCT00384150
Last Modified:
6/8/2004
 
First Published:
2/21/2003
2.
Phase I/II Study of IDEC-114 Monoclonal Antibody and Rituximab in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0207122
IDEC-114-21, UNMC-04703, NCT00056043
Last Modified:
7/10/2007
 
First Published:
6/25/2005
3.
Phase II Study of Rituximab and Galiximab in Patients With Previously Untreated CD20-Positive Bulky Stage II or Stage III or IV Follicular Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CALGB-50402
CALGB-50402, NCT00117975
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute